Product Name:O-[2-[(2-methylpropan-2-yl)oxy]ethyl]hydroxylamine

IUPAC Name:O-[2-(tert-butoxy)ethyl]hydroxylamine

CAS:1023742-13-3
Molecular Formula:C6H15NO2
Purity:95%+
Catalog Number:CM325604
Molecular Weight:133.19

Packing Unit Available Stock Price($) Quantity
CM325604-100g in stock ƚƚǠ
CM325604-500g in stock ȤœŸƚ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:1023742-13-3
Molecular Formula:C6H15NO2
Melting Point:-
Smiles Code:NOCCOC(C)(C)C
Density:
Catalog Number:CM325604
Molecular Weight:133.19
Boiling Point:
MDL No:
Storage:

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Encorafenib plus Binimetinib
U.S. FDA approved Pfizer's BRAFTOVI® (Encorafenib) + MEKTOVI® (Binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. The FDA's approval is based on data from the ongoing Phase 2 PHAROS clinical trial. Encorafenib is an oral small molecule BRAF kinase inhibitor, and Binimetinib is an oral small molecule MEK inhibitor targeting key proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK).
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.